D. Jackson, B. Kent, M. Humbert, L. Heaney, S. Korn, M. Keith, S. Siddiqui, B. Cook, E. G. Gil, A. D. G. Miller
{"title":"Benralizumab控制的严重嗜酸性哮喘患者使用ICS/LABA治疗作为必要的抗炎缓解剂:SHAMAL IV期临床研究","authors":"D. Jackson, B. Kent, M. Humbert, L. Heaney, S. Korn, M. Keith, S. Siddiqui, B. Cook, E. G. Gil, A. D. G. Miller","doi":"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3020","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":129045,"journal":{"name":"B31. ASTHMA CLINICAL TRIALS","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Enabling Reductions in Maintenance ICS/LABA Therapy Using as Needed Anti-Inflammatory Reliever for Patients with Severe Eosinophilic Asthma Controlled with Benralizumab: SHAMAL Phase IV Clinical Study\",\"authors\":\"D. Jackson, B. Kent, M. Humbert, L. Heaney, S. Korn, M. Keith, S. Siddiqui, B. Cook, E. G. Gil, A. D. G. Miller\",\"doi\":\"10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":129045,\"journal\":{\"name\":\"B31. ASTHMA CLINICAL TRIALS\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B31. ASTHMA CLINICAL TRIALS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B31. ASTHMA CLINICAL TRIALS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Enabling Reductions in Maintenance ICS/LABA Therapy Using as Needed Anti-Inflammatory Reliever for Patients with Severe Eosinophilic Asthma Controlled with Benralizumab: SHAMAL Phase IV Clinical Study